293b cpd has been researched along with cromakalim in 1 studies
| Studies (293b cpd) | Trials (293b cpd) | Recent Studies (post-2010) (293b cpd) | Studies (cromakalim) | Trials (cromakalim) | Recent Studies (post-2010) (cromakalim) |
|---|---|---|---|---|---|
| 100 | 0 | 16 | 1,388 | 20 | 79 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baró, I; Charpentier, F; Escande, D; Kunzelmann, K; Loussouarn, G; Mohammad-Panah, R | 1 |
1 other study(ies) available for 293b cpd and cromakalim
| Article | Year |
|---|---|
KvLQT1 potassium channel but not IsK is the molecular target for trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl- chromane.
Topics: Animals; Binding Sites; Chromans; COS Cells; Cromakalim; Kinetics; Long QT Syndrome; Potassium; Potassium Channel Blockers; Potassium Channels; Sulfonamides | 1997 |